PI
SAGE icon

Pennant Investors’s Sage Therapeutics SAGE Stock Holding History

Pennant Investors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,500
Closed -$190K – 42
2024
Q2 		$190K Hold
17,500
– – 0.05% 38
2024
Q1 		$328K Hold
17,500
– – 0.08% 34
2023
Q4 		$379K Buy
+17,500
New +$347K 0.08% 31

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Pennant Investors's SAGE Position: Q3 2024 in Review

Pennant Investors sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 17,500 shares — an estimated $190K sold.

Pennant Investors first reported a position in SAGE in Q4 2023 and held it in 3 quarters. The position peaked at $379K in Q4 2023. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Pennant Investors reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 17,500 Sage Therapeutics shares in Q3 2024, an estimated $190K.
  • Pennant Investors first reported a position in Sage Therapeutics in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Sage Therapeutics position peaked at $379K in Q4 2023.
  • 176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.